Forcefield Therapeutics is a pioneer of best-in-class therapeutics to retain heart function via the protection of cardiomyocytes. Forcefield Tx was founded on the work of Professor Mauro Giacca, an authority in cardiovascular disease and genetic biology and the Heat of the School of Cardiovascular Medicine and Sciences at King’s College London as well as industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI). Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by a leading FTSE 250 healthcare company, Syncona.
Company Details
- Employees
- 8
- Address
- 8 Bloomsbury Street, London,england Wc1b 3qa,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://forcefieldtx.com
- HQ
- London, England
Forcefield Therapeutics Questions
Forcefield Therapeutics's website is https://forcefieldtx.com
Forcefield Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/forcefieldtx
Forcefield Therapeutics has
8 employees.
View email and phone details for 8
employees at Forcefield Therapeutics.
Forcefield Therapeutics's industry is
Biotechnology Research
Forcefield Therapeutics's top competitors are
Beacon Therapeutics,
Resolution Therapeutics,
Aviadobio,
Achilles Therapeutics Plc,
Spur Therapeutics,
Purespring Therapeutics,
Syncona Limited,
Biogen,
Quell Therapeutics,
Blueprint Medicines.
Forcefield Therapeutics's categories are Biotechnology Research
